

Microwave assisted synthesis of amide derivatives of the drug ciprofloxacin and screening the biological properties

Nadhir N. A.Jafar^{1*}, Nadia SadiqMajeed²


¹Department of Chemistry, University of Babylon, Iraq

²Department of Chemistry, University of Kufa, Iraq

Abstract : It is synthesis of organic compounds derived from drug ciprofloxacin as amide form with the help of microwave irradiation. It created a series of these compounds (**3a-3n**) by ester derivative as intermediate. These compounds have been diagnosed using the following spectroscopic methods: IR, ¹HNMR and ¹³CNMR as well as the use of elemental microanalysis (CHN) found that all spectra match the look and structural molecule. All compounds proved better effective against bacterial Gram-negative and positive like bacteria type (*Proteus mirabilis*, *Escherichia coli*, *Staphylococcus aureus*, *Granuticetella adiacens*).
Keywords: Antibacterial, Thiazole, Ciprofloxacin, DNA gyrase, fluoroquinolones, Amide.

1. Introduction:

Drugs that has the composition of chemical fluoroquinolones such as ciprofloxacin, norfloxacin and sparfloxacin proved highly effective and wide acceptance in various bacterial infections¹⁻⁶. The activity derived from the inhibition of action bacterial DNA gyrase, this enzyme is responsible for DNA replication⁷⁻¹¹. In addition, the deployment of the anti-containing fluoroquinolones fitted carboxyl group at the site N-1, showed as anti HIV¹². Quinolone antibiotics are used as a treatment widely because of their safety, address a wide range of bacteria and less resistance¹³⁻¹⁶. Many of the research conducted on ciprofloxacin for the synthesis of new antibiotics, which chose the site 7 to prepare new derivatives as anti-mycobacterial activity, antibacterial and antifungal¹⁷⁻²⁴.



Amines play a key role in the pharmaceutical manufacturing process as well as in the formation of the main association in proteins, amides represent a very well-known brand drugs²⁵. For example, Atorvastatin, blocks the production of cholesterol²⁶, Lisinopril inhibitor of angiotensin enzyme²⁷, Diltiazem calcium channel blocker²⁸, Valsartan blockade of angiotensin receptors²⁹. Direct interaction between the carboxyl group and amine to prepare amides requires heating up more than 200°C to get rid of the water generated³⁰⁻³². Therefore it requires first convert the hydroxyl group to a good leaving group before adding it to the amine was to

transferred to the ester group as an intermediate and then synthesis of amines³³. A continuation of previous work in the synthesis of new amide derivative³⁴, and furthermore fluoroquinolones represent best synthetic antibacterial agents³⁵⁻⁴⁴, so we reported and described the synthesis of new series of fluoroquinolone amide derivatives via carboxylic group at C-3 that was esterified and subjected to nucleophilic attack at the carbonyl carbon by different amines and screening in vitro of its antibacterial activity aims at further investigation of ciprofloxacin amides derivatives against some Gram-positive and Gram-negative bacteria.

2. Experimental

2.1. Materials and methods

All the chemical materials equipped by Sigma-Aldrich, Merck, Scharlau and Fluka company, the apparatus used in current research (Stuart) melting point (SMP30, England). UV- lamp at 254- 366 nm; Thermo- Circulator (Labtech), England. Infrared red were measured on (Shimaduz, Japan) (FT -IR)-IR Prestige-21 Spectrophotometer in Kufa University. ¹H- NMR Spectrophotometer (Avance III, Bruker 300 MHz) with a scale in ppm and TMS as internal standard, all ¹H- NMR Spectra were examined in dimethyl sulfoxide and 100 MHz ¹³C- NMR Spectrometer in university of Toronto. Microwave oven LG MOD MH7947S 1450- 1150 W.

2.2. General procedure for preparation of amide derivatives [31]:

Synthesis of different derivatives of ciprofloxacin was attempted with equimolecular of various aromatic amines. Ciprofloxacin (0.001 moles) was added to the round bottomed flask having (30 ml) of absolute ethanol, (ml) of sulphuric acid was added to the flask and the reaction was refluxed (400W, 20%) in microwave oven and irradiated about 20 min, After the depletion of ciprofloxacin and forming ciprofloxacin ester intermediate (Tested by TLC) 0.001 molar solution of aromatic amines (prepared in ethanol) were added separately and the reaction was again refluxed for about 15 min. till completion and Thin layer chromatography was used to monitor reaction. The volume of the reaction mixture was then reduced by rotary- evaporation. The precipitates were filtrated off, washed with ethanol to give compound.

2.2.1.1-cyclopropyl-6-fluoro-N-(3-hydroxyphenyl)-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxamide (3a):

White, Yield: 66%, M.P.: 276 °C FT- IR (KBr cm⁻¹): 3435 v(OH) (phenol), 1720v(C=O) (amide), 1629 vC=O (pyridone). ¹H-NMR (300 MHz-DMSO-*d*₆- δ , ppm): 0.67- 1.9 (m, 5H, *H*_{cyclopropane}), 2.90- 3.60 (m, 8H, *H*_{piperazine}), 4.0 (s, 1H, N-CH=C-C=O), 5.0 (m, 1H, NH_{piperazine}), 6.70- 7.90 (m, 7H, Ar-*H*) 9.03 (s, 1H, C=O-NH), 11.01(s, 1H, Ar-OH). ¹³C-NMR (300 MHz-DMSO-*d*₆, δ , ppm): 205 (1C, C=O_{pyridon}), 160 (1C, C=O-NH), 140- 134 (14C, *C*_{aromatic}), 104 (2C, C=C), 32- 36 (4C, *C*_{piperazine}), 14- 18 (3C, *C*_{cyclopropane}). Anl. calcd. for C₂₃H₂₃FN₄O₃: C, 65.39; H, 5.49; N, 13.26. Found: C, 65.44; H, 5.53; N, 13.20%.

2.2.2.1-cyclopropyl-6-fluoro-N-(4-bromophenyl)-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxamide (3b):

White, Yield: 60%, M.P: 285 °C, FT-IR (KBr, cm⁻¹): 3516 v(OH) (tautomerism), 3414 v(N-H) (amide), 1720 v(C=O) (amide), 1629 v(C=O) (pyridone). ¹H-NMR (300 MHz, DMSO-*d*₆, δ , ppm): 0.74- 1.76 (m, 5H, *H*_{cyclopropane}), 3.0- 4.33 (m, 8H, *H*_{piperazine}), 4.50 (s, 1H, N-CH=C-C=O), 5.60 (t, 1H, NH_{piperazine}), 6.58- 7.83 (m, 7H, Ar-*H*), 9.0 (s, 1H, C=O-NH). ¹³C-NMR (300 MHz, DMSO-*d*₆, δ , ppm): 210 (1C, *C*_{pyridone}), 164 (1C, C=O-NH), 114- 134 (14C, *C*_{aromatic}), 106 (1C, C=C), 36 (4C, *C*_{piperazine}), 16 (3C, *C*_{cyclopropane}). Anl. calcd. for C₂₃H₂₂BrFN₄O₂:C, 56.92; H, 4.57; N, 11.54. Found: C, 56.99; H, 4.60; N, 11.50%.

2.2.3.1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-N-(pyridin-2-yl)-1,4-dihydroquinoline-3-carboxamide (3c):

White, Yield: 72%, M.P.: 272 °C, FT- IR (KBr, cm⁻¹): 3417 v(N-H) (amide), 1720 v(C=O) (amide), 1629 v(C=O) (pyridone). ¹H-NMR (300 MHz, DMSO-*d*₆, δ , ppm): 0.94- 1.86 (m, 5H, *H*_{cyclopropane}), 2.4- 2.7 (m, 8H, *H*_{piperazine}), 4.50 (s, 1H, N-CH=C-C=O), 5.03- 5.99 (t, 1H, NH_{piperazine}), 7.01- 7.63 (m, 7H, Ar-*H*), 9.0 (s, 1H, C=O-NH). Anl. calcd. for C₂₂H₂₂FN₅O₂:C, 64.85; H, 5.44; N, 17.19. Found: C, 64.95; H, 5.49; N, 17.22%.

2.2.4.1-cyclopropyl-6-fluoro-N-(4-methoxyphenyl)-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxamide (3d):

White, Yield 75%, M.P.: 279 °C, FT-IR (KBr, cm^{-1}) 3437v(N-H+ OH) (amide+ carboxylic acid), 1728v(C=O) (amide), 1666v(C=N), 1627 v(C=O) (pyridone). $^1\text{H-NMR}$ (300 MHz, DMSO-*d*6, δ , ppm): 0.9-1.02 (m, 5H, $H_{\text{cyclopropane}}$), 2.60- 2.90 (m, 8H, $H_{\text{piperazine}}$) 3.86 (s, 3H, O-CH₃), 3.96 (s, 1H, N-CH=C-C=O), 4.62 (br, 1H, OH-C=N_{tautomerism}), 6.22- 7.87 (m, 7H, H_{aromatic}), 9.36 (s, 1H, C=O-NH), $^{13}\text{C-NMR}$ (300MHz, DMSO-*d*6, δ , ppm): 215 (1C, C_{pyridone}), 165 (1C, C=O-NH), 114- 134 (14C, C_{aromatic}) 102 (2C, C=C), 80 (1C, OCH₃), 18- 22 (3C, $C_{\text{cyclopropane}}$). Anl. calcd. for C₂₄H₂₅FN₄O₃: C, 66.04; H, 5.77; N, 12.84, Found: C, 66.02; H, 5.67; N, 12.88%.

2.2.5.4-(1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxamido) benzoic acid (3e):

White, Yield: 62%, MP.: 274 °C, FT-IR (KBr cm^{-1}): 3435 v(N-H+ OH) (amide+ carboxylic acid), 1720v(C=O) (amide), 1629 v C=O (pyridone), 1271 v(OH) (OH bending vibration carboxylic acid). $^1\text{H-NMR}$ (300 MHz, DMSO-*d*6, δ , ppm), 1.40- 1.58 (m, 5H, $H_{\text{cyclopropane}}$), 2.48- 2.84 (d, 4H, $H_{\text{piperazine}}$), 5.08 (br, 1H, OH-C=N_{tautomerism}), 6.62- 7.84 (m, 7H, Ar-*H*), 9.41 (s, 1H, C=O-NH), 13.28 (s, 1H, COOH). $^{13}\text{C-NMR}$ - MHz, DMSO- *d*6, δ , ppm): 205 (1C, C_{pyridone}), 190 (1C, COOH), 168 (1C, C=O-NH), 118- 135 (14C, C_{aromatic}), 104- 106 (2C, C=C), 12- 16 (3C, $C_{\text{cyclopropane}}$), 34- 36 (4C, $C_{\text{piperazin}}$). Anl. calcd. for C₂₄H₂₃FN₄O₄: C, 63.99; H, 5.15; N, 12.44. Found: C, 63.90; H, 5.10; N, 12.40%.

2.2.6.1-cyclopropyl-6-fluoro-N-(2-hydroxyphenyl)-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxamide (3f):

White, Yield: 68%, M.P.: 278 °C, FT- IR (KBr, cm^{-1}), 3437 v(OH) (Phenol), 1718v(C=O) (amide), 1629 v(C=O) (pyridone). $^1\text{H-NMR}$ (300 MHz-DMSO-*d*6, δ , ppm): 0.8- 1.4 (m, 5H, $H_{\text{cyclopropane}}$), 2.5- 3.47 (m, 8H, N-CH₂-CH₂-N), 3.94 (s, 1H, N-CH=C-C=O), 5.0 (s, 1H, $H_{\text{piperazine}}$), 7.72- 7.80 (m, 7H, Ar-*H*), 9.0 (s, 1H, C=O-NH), 11.0 (s, 1H, OH). $^{13}\text{C-NMR}$ (300 MHz-DMSO-*d*6, δ , ppm): 205 (1C, C_{pyridone}), 160 (1C, C=O-NH), 140- 134(14C, C_{aromatic}), 104 (2C, C=C), 32- 36 (4C, $C_{\text{piperazine}}$), 14- 18 (3C, $C_{\text{cyclopropane}}$). Anl. calcd. for C₂₃H₂₃FN₄O₃: C, 65.39; H, 5.49; N, 13.26. Found: C, 65.48; H, 5.50; N, 13.22%

2.2.7.1-cyclopropyl-6-fluoro-N-(4-hydroxyphenethyl)-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxamide (3g):

White, Yield: 73%, M.P.: 282 °C, FT-IR (KBr, cm^{-1}): 3437 v(NH+ OH) (amide+ phenol), 1718 v(C=O) (amide), 1664v(C=N_{tautomerism}), 1629 v(C=O) (pyridone). $^1\text{H-NMR}$ (300 MHz-DMSO-*d*6, δ , ppm), 0.8- 1.70 (m, 5H, $H_{\text{cyclopropane}}$), 1.80- 2.30 (m, 8H, $H_{\text{piperazine}}$), 3.10- 3.90 (m, 4H, N-CH₂-CH₂-N), 5.0 (s, 1H, NH_{piperazine}), 6.90- 7.80 (m, 7H, Ar-*H*), 9.2 (s, 1H, C=O-NH), 11.01(s, 1H, Ar-OH). $^{13}\text{C-NMR}$ 300 MHz-DMSO-*d*6, δ , ppm): 215 (1C, C_{pyridone}), 165 (1C, C=O-NH), 116- 135 (14C, C_{aromatic}), 115 (2C, C=C), 34- 38 (4C, $C_{\text{piperazine}}$), 12 (3C, $C_{\text{cyclopropane}}$), 22 (2C, NH-CH₂-CH₂-N), 96.0(1C, C=N_{tautomerism}). Anl. calcd. for C₂₅H₂₇FN₄O₃: C, 66.65; H, 6.04; N, 12.44. Found: C, 66.69; H, 6.09; N, 12.49%.

2.2.8.4-(1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxamido) butanoic acid (3h):

White, yield: 76%, M.P.: 268 °C, FT- IR (KBr, cm^{-1}): 3439 v(O-H) (carboxylic acid), 1718 v(C=O) (amide), 1629v(C=O) (pyridone), 1271 v(OH) (OH bending vibration carboxylic acid). $^1\text{H-NMR}$ (300 MHz-DMSO-*d*6, δ , ppm), 1.0- 1.58 (m, 5H, $H_{\text{cyclopropane}}$), 2.48- 2.84(m, 4H, N-CH₂-CH₂-N), 3.21- 3.40 (N-CH₂-CH₂-CH₂-COO), 4.32 (s, 1H, N-CH=C-C=O), 5.08 (s, 1H, NH_{piperazine}), 7.07- 7.84 (m, 3H, Ar-*H*), 9.11(s, 1H, C=O-NH), 13.23 (s, 1H, COOH). $^{13}\text{C-NMR}$ 300 MHz-DMSO-*d*6, δ , ppm): 215 (1C, C_{pyridone}), 190 (1 C, COOH), 160 (1C, C=O-NH), 115- 135 (8C, C_{aromatic}), 100 (2C, C=C), 32- 38 (4C, $C_{\text{piperazine}}$), 20- 22 (3C, -CH₂CH₂CH₂-), 14- 16 (3C, $C_{\text{cyclopropane}}$). Anl. calcd. for C₂₀H₂₃FN₄O₄: C, 59.69; H, 5.76; N, 13.92. Found: C, 59.65; H, 5.796; N, 13.89%.

2.2.9. *N*-(4-(benzo[d]thiazol-2-yl)phenyl)-1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxamide (3i):

Pink, Yield: 68%, M.P.: 286 °C, FT- IR (KBr, cm^{-1}) 3435 $\nu(\text{NH})$ (amide), 3238 $\nu(\text{OH})$ (tautomerism), 1716 $\nu(\text{C}=\text{O})$ (amide), 1668 $\nu(\text{C}=\text{N})$ (tautomerism), 1625 $\nu(\text{C}=\text{O})$ (pyridone), 1525 $\nu(\text{C}=\text{S})$ (hetero cyclic ring). $^1\text{H-NMR}$ (300 MHz-DMSO-*d*₆, δ , ppm): 1.0- 1.40 (m, 5H, $H_{\text{cyclopropane}}$), 2.70- 3.50 (m, 4H, N-CH₂-CH₂-N), 3.90 (s, 1H, N-CH=C-C=O), 5.10 (s, 1H, $\text{NH}_{\text{piperazine}}$), 6.51-7.94 (s, 1H, $\text{NH}_{\text{benzothiazole}}$), 9.65 (s, 1H, C=O-NH). $^{13}\text{C-NMR}$ (300MHz-DMSO-*d*₆, δ , ppm): 205 (1C, C_{pyridone}), 160 (1C, C=O-NH), 145 (1C, C=N), 118- 132 (13C, C_{aromatic}), 105 (2C, C=C), 30- 34 (4C, $C_{\text{piperazine}}$), 9- 12 (3C, $C_{\text{cyclopropane}}$). Anl. calcd. for C₃₀H₂₆FN₅O₂S: C, 66.77; H, 4.86; N, 12.98. Found: C, 66.79; H, 4.88; N, 13.00%.

2.2.10. 1-cyclopropyl-6-fluoro-*N*-(4-nitrophenyl)-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxamide (3j):

Yellow, Yield: 58%, M.p.: 279 °C, FT-IR (KBr, cm^{-1}): 3433 $\nu(\text{N-H})$ (amide), 3213 $\nu(\text{OH})$ (tautomerism), 1718 $\nu(\text{C}=\text{O})$ (amide), 1625 $\nu(\text{C}=\text{O})$ (pyridone). $^1\text{H-NMR}$ (300 MHz-DMSO- *d*₆- δ , ppm): 0.70- 1.20 (m, 5H, $H_{\text{cyclopropane}}$), 2.70- 3.90 (m, 8H, $H_{\text{piperazine}}$), 4.10 (s, 1H, N-CH=C-C=O), 5.05 (m, 1H, $\text{NH}_{\text{piperazine}}$) 6.90- 7.67 (m, 7H, Ar-*H*), 9.10 (s, 1H, C=O-NH). $^{13}\text{C-NMR}$ – 300 MHz, DMSO-*d*₆, δ , ppm): 215 (1C, C_{pyridone}), 168 (1C, C=O-NH), 108 (2C, C=C), 118- 135 (14C, C_{aromatic}), 30- 34 (4C, $C_{\text{piperazine}}$), 12- 14 (3C, $C_{\text{cyclopropane}}$). Anl. calcd. for C₂₃H₂₂FN₅O₄: C, 61.19; H, 4.91; N, 15.51. Found: C, 61.25; H, 4.93; N, 15.50

2.2.11. 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-*N*-(pyrimidin-2-yl)-1,4-dihydroquinoline-3-carboxamide (3k):

White, Yield: 69%, M.P.: 277 °C, FT- IR (KBr, cm^{-1}): 3435 $\nu(\text{N-H})$ (amide), 1720 $\nu(\text{C}=\text{O})$ (amide), 1629 $\nu(\text{C}=\text{O})$ (pyridone). $^1\text{H-NMR}$ (300 MHz, DMSO-*d*₆, δ , ppm): 1.0-1.04 (m, 4H, $H_{\text{cyclopropane}}$), 2.7-3.5 (m, 8H, $H_{\text{piperazine}}$), 3.90 (s, 1H, N-CH=C-C=O), 5.10 (m, 1H, $\text{NH}_{\text{piperazine}}$) 6.51- 7.94 (m, 6H, $H_{\text{aromatic \& benzothiazole}}$), 9.65 (s, 1H, C=O-NH). $^{13}\text{C-NMR}$ – 300MHz, DMSO-*d*₆, δ , ppm): 200 (1C, C=O). 192 (1C, C=O-NH), 146 (1C, C=N), 118- 130 (1C, C_{pyridone}), 104 (2C, C=C), 97 (1C, OH-C=N_{tautomerism}), 34- 38 (4C, $C_{\text{piperazine}}$), 12- 15 (3C, $C_{\text{cyclopropane}}$). Anl. calcd. for C₂₁H₂₁FN₆O₂: C, 61.76; H, 5.18; N, 20.58.

Found: C, 61.77; H, 5.20; N, 20.56%.

2.2.12. *N*-(2-chlorophenyl)-1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxamide (3l):

Yellow, Yield: 84%, M.P.: 281 °C, FT-IR (KBr, cm^{-1}): 3435 $\nu(\text{N-H} + \text{OH})$ (amide+ O-H tautomerism), 1720 $\nu(\text{C}=\text{O})$ (amide), 1666 $\nu(\text{C}=\text{N})$ (tautomerism), 1629 $\nu(\text{C}=\text{O})$ (pyridone). $^1\text{H-NMR}$ (300 MHz, DMSO-*d*₆, δ , ppm): 0.74- 1.17 (m, 5H, $H_{\text{cyclopropane}}$), 2.90- 3.90 (m, 8H, $H_{\text{piperazine}}$), 4.0 (s, 1H, N-CH=C-C=O), 5.0 (t, 1H, $\text{NH}_{\text{piperazine}}$), 7.0- 7.90 (m, 7H, Ar-*H*), 9.10 (s, 1H, C=O-NH). $^{13}\text{C-NMR}$ (300 MHz, DMSO-*d*₆, δ , ppm): 215 (1C, C_{pyridone}), 165 (1C, C=O-NH), 112- 134 (14C, C_{aromatic}), 108 (1C, C=C), 36 (4C, $C_{\text{piperazine}}$), 15 (3C, $C_{\text{cyclopropane}}$). Anl. calcd. for C₂₃H₂₂ClFN₄O₂: C, 62.66; H, 5.03; N, 12.71. Found: C, 62.64; H, 5.06; N, 12.65%.

2.2.13. 1-cyclopropyl-6-fluoro-*N*-(2-methoxyphenyl)-4-oxo-7-(piperazin-1-yl)-1,4-Dihydroquinoline-3-carboxamide (3m):

White, Yield: 74%, M.P.: 284 °C, FT- IR (KBr, cm^{-1}), 3435 $\nu(\text{N-H} + \text{OH})$ (amide+ carboxylic acid), 1730 $\nu(\text{C}=\text{O})$ (amide), 1664 $\nu(\text{C}=\text{N})$, 1627 $\nu(\text{C}=\text{O})$ (pyridone). $^1\text{H-NMR}$ (300 MHz, DMSO-*d*₆, δ , ppm): 0.92- 1.04 (m, 5H, $H_{\text{cyclopropane}}$), 2.61-2.92 (m, 8H, $H_{\text{piperazine}}$) 3.88 (s, 3H, O-CH₃), 3.98 (s, 1H, N-CH=C-C=O), 4.62 (br, 1H, OH-C=N_{tautomerism}), 6.24- 7.89 (m, 7H, H_{aromatic}), 9.36 (s, 1H, C=O-NH), $^{13}\text{C-NMR}$ (300MHz, DMSO-*d*₆, δ , ppm): 210 (1C, C_{pyridone}), 165 (1C, C=O-NH), 114- 132 (14C, C_{aromatic}) 102 (2C, C=C), 82 (1C, OCH₃), 18- 24 (3C, $C_{\text{cyclopropane}}$). Anl. calcd. for C₂₄H₂₅FN₄O₃: C, 66.04; H, 5.77; N, 12.84. Found: C, 66.02; H, 5.67; N, 12.88%.

2.2.14. *N*-(2-bromophenyl)-1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxamide (3n):


Brown, Yield 60%, M.P: 277 °C, FT- IR (KBr cm^{-1}): 3516 $\nu(\text{OH}_{\text{totomerzium}})$, 3414 $\nu\text{N-H}(\text{amide})$, 1720 $\nu\text{C=O}(\text{amide})$, 1629 $\nu\text{C=O}(\text{pyridone})$. $^1\text{H-NMR}$ (300 MHz, $\text{DMSO-}d_6$, δ , ppm): 0.76- 1.75 (m, 5H, $H_{\text{cyclopropane}}$), 3.89- 4.23 (m, 8H, $H_{\text{piperazine}}$), 4.55 (s, 1H, N-CH=C-C=O), 5.61 (t, 1H, $\text{NH}_{\text{piperazine}}$), 6.58- 7.78 (m, 7H, Ar-H), 9.0 (s, 1H, C=O-NH). $^{13}\text{C-NMR}$ (300 MHz, $\text{DMSO-}d_6$, δ , ppm): 212 (1C, C_{pyridone}), 165 (1C, C=O-NH), 116- 136 (14C, C_{aromatic}), 108 (1C, C=C), 36 (4C, $C_{\text{piperazine}}$), 17 (3C, $C_{\text{cyclopropane}}$). Anl. calcd. for $\text{C}_{23}\text{H}_{22}\text{BrFN}_4\text{O}_2$: C, 56.92; H, 4.57; N, 11.54. Found: C, 56.90; H, 4.62; N, 11.49%.

2.3. Antibacterial activity assay: [33]

An antibacterial activity has been conducted according to piercing method, all ciprofloxacin amide derivatives **3a- 3n** were tested by this method against four types of bacteria gram negative such as *Escherichiacoli*, *Proteus mirabilis* and gram positive like *Staphylococcus aureus*, *Granuticetellaadiacens*. All derivatives were dissolved in (3) dissimilar concentration 0.01 gm, 0.005 gm, 0.001 gm in 10 ml of water, the surface of solid culture media (Nutrient Agar) dried and applied on the plates which had been streaked with standardized bacterial inoculums and incubated at 37 °C for 24h. This technique is based on the determination of an inhibited zone (in mm) proportional to the bacteria in the plates and the results were compared with the antibacterial activity of ciprofloxacin drug.

3. Results and discussion


Potential activity of the ciprofloxacin **1** for treatment of different strains of Gram positive and Gram negative organism prompted us to introduce much more amine groups to prepared amide, aiming to develop a new compounds having novel properties.



Therefore, treatment of ciprofloxacin **1** with absolute ethanol alcohol with catalytic amount of concentration sulphuric acid to synthesis ester **2** as intermediate after 20 minutes irradiated by microwave, following the reaction mixture by (TLC) when completion the reaction and consumption of ciprofloxacin forming the ester as intermediate, added the aromatic or aliphatic amine **3a- 3n** and reflux by microwave


irradiation for about 15-20 minutes. All synthesis amide compounds **3a- 3n** were washed by (ethanol: chloroform) 2:8 after evaporation by rotary evaporator yielded from (58-84) % (scheme 1).

In IR spectra noticed the absence of the band at $\nu = 3527 \text{ cm}^{-1}$ OH group for carboxylic acid and presence the absorption band $\nu = 3200- 3414 \text{ cm}^{-1}$ for NH vibration of amide group only amide derivate **3a, 3f and 3g** containing OH group as substituted in aromatic ring of amide were give absorption band of aromatic OH in the same region, the carboxylic C=O absorption band $\nu = 1707 \text{ cm}^{-1}$ was shifted to $\nu = 1720 \text{ cm}^{-1}$ for amide formation, indicating the consumption of carboxylate groupin ester and amide formation as in figure 1.



In ^1H NMR likewise, in IR spectra the absence of resonance of acidic proton at $\delta = 11.02 \text{ ppm}$ in ciprofloxacin, all amide derivatives showed a singlet signals in the region $\delta = 9.0- 9.65 \text{ ppm}$, the difference in chemical shift of all synthesis compounds showed a significant $\delta = 0.65 \text{ ppm}$. All other protons practically remained same as in original molecule (ciprofloxacin), further signals back to the chemical structures as in spectral date. But ^{13}C NMR of all synthesis compounds exhibited a clear signal between $\delta = 160- 186 \text{ ppm}$ for carbon of amide for aromatic derivative except compound **3h** showed this signal in $\delta = 192 \text{ ppm}$ because for its aliphatic amide derivative, there is no significant difference in the chemical shift of carbon of carbonyl in pyridone its between $\delta = 205- 215 \text{ ppm}$ according to their structure. All these data were confirmed the structures of synthesized amide as well as the micro elemental analysis (CHN) fitted these compounds.

However, Figure 2 shows the resonances of carbon for carbonyl amide of compounds **3a** in comparison with compound **3b**. The resonance of carbonyl carbon (pyridone) ring of **3a** and **3b** in the not at same region at $\delta = 205$ and 215 ppm respectively shifted $\sim 5 \text{ ppm}$, whereas the resonance of carbon of These shifts in the ^{13}C NMR resonances are indicative of the tautomeric effects form and confirmed by ^1H NMR when the shifts between **3a** and **3b** was $\sim 4.41 \text{ ppm}$, as explain in this figure 2.



Antibacterial activity was determined by measuring the inhibition zone in mm, the preliminary result show the increasing of the inhibition zone when increasing the concentration of all compounds with all type of bacteria table 1. The results showed that compound **3i** was the most effective and highest activity against all types of bacteria because this compound contains has a thiazole heterocyclic ring. In particular, compounds **3a**, **3f** and **3g** were found to be respectable activity against gram- negative (*E. coli*, *proteus mirabilis*) because it contains OH groups in different positions. The compounds **3a**, **3l** and **3m** derivatives exhibited better activity against *Staphylococcus aureus* and *Granticetellaadiaceus* because the compounds containing bromine and chlorine atoms substituted in the phenyl ring. compounds **3e** and **3f** showed decrease in their activity against all tested bacteria. Moreover, compounds **3d** and **3m** derivatives exhibited excellent activity towards *E. coli* and *proteus mirabilis* bacteria for containing methoxy group substituted in the phenyl ring, so these excellent results suggested us to synthesis new derivatives to further study.

Table 1. Zone inhibition (mm) of ciprofloxacin and their Amide derivatives (3a-3n) against various microorganisms.

Inhibition zone (mm)												Conc µg/L			
Proteus mirabilis			Escherichia Coli			Granuticetella adiacens			Staphylococcus Aureus						
11	16	12	14	22	25	9	13	15	11	14	16	1	0.5	0.1	3a
12	15	19	13	15	19	15	18	21	9	12	20	1	0.5	0.1	3b
12	19	22	14	18	28	11	15	17	13	14	17	1	0.5	0.1	3c
15	20	27	15	19	26	10	13	20	10	11	24	1	0.5	0.1	3d
13	15	18	11	14	17	15	19	16	10	12	14	1	0.5	0.1	3e
14	20	24	15	19	26	17	18	21	8	10	16	1	0.5	0.1	3f
16	22	26	18	25	30	10	12	14	12	16	18	1	0.5	0.1	3g
10	15	17	10	14	18	12	17	22	9	12	17	1	0.5	0.1	3h
16	24	32	18	22	30	18	21	30	12	18	26	1	0.5	0.1	3i
14	19	29	15	19	26	14	17	19	10	14	16	1	0.5	0.1	3j
20	25	30	18	20	29	12	17	22	13	16	22	1	0.5	0.1	3k
14	25	18	12	16	17	11	14	21	10	16	30	1	0.5	0.1	3l
15	20	18	13	18	19	12	16	24	10	14	28	1	0.5	0.1	3m
18	20	25	18	24	30	11	14	21	15	18	20	1	0.5	0.1	3n
11	13	17	8	11	14	9	10	12	8	10	13	1	0.5	0.1	Cip

Conclusions

The development of antibiotics for bacterial pathogenesis has a special importance in the treatment of infection diseases. The important conclusion is that the biological effectiveness of the best in the compound **3i** and **3k**, because their constituents containing organic heterocyclic rings. All of these compounds showed high effective even at low concentrations. The results also showed that all compounds are effectively much higher than the effectiveness of ciprofloxacin. Many compounds like **3e**, **3g**, **3i**, **3k**, **3l** and **3m** are a promising agent for further structural modification and pharmacological evaluation as target treatment of infections caused by these types of bacteria.

References

- Gootz, T. D.; Brighty, K. E. Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects. *Med. Res. Rev* 1996, 16, 433-486
- Syed Shafi. S, Senthilkumar. S. Synthesis and Microbial Activity of Novel Quinazoline Derivatives. *International Journal of ChemTech Research*. 2015, 8, 1, 164-169.
- Moumita Roy. C. Bacterial persistence: molecular mechanisms, biofilm, pathogenicity and eradication. *International Journal of ChemTech Researc*. 2015, 8, 2, 204-212.

4. Geethalaksmi V, Theivarasu C. Synthesis and Characterization of Samarium(III)(and Gadolinium(III) Complexes Containing 2-Methoxy-6-((2-(Piperazin-1yl)Ethylimino)Methyl) Phenol as Ligand. *International Journal of ChemTech Research* 2016, 9, 5, 941-949.
5. Omran L, Askar E. Antibiotic Sensitivity Patterns of the Most Common Bacteria
6. Isolated from Al-Mouwasat University Hospital in 2015, Syria, *International Journal of ChemTech Research*, 2016, 9, 1, 113-119.
7. Llorente, B.; Leclerc, F.; Cedergren, R. Using SAR and QSAR analysis to model the activity and structure of the quinolone-DNA complex. *Bioorg. MedChem* 1996, 4, 61-71.
8. Arkady, M.; Muhammad, M.; Xilin, Z.; Natalia, K.; Gan, L.; Lisa, M.; Hiroshi, H.; Kevin R.; Marks, J.; Kerns, M.; and Karl Drlica.; Fluoroquinolone-Gyrase-DNA Complexes. *J BiolChem*, 2014, 18, 289. 12300-12312.
9. Rajesh B, Sanjay D. Synthesis, characterization, molecular docking and evaluation of antimicrobial activity of some 3-heteroaryl substituted chromen-2-one derivatives. *International Journal of ChemTech Research* 2015, .7, No.3, pp 471-480.
10. Moumita R. C. Bacterial persistence: molecular mechanisms, biofilm, pathogenicity and eradication. *International Journal of ChemTech Research*. 2015, 8, 2, 204-212.
11. Anusuya T, Pandian K, Facile Synthesis of Fe₃O₄@Ag Magnetic Nanoparticles and Their Application in Detection of Pathogenic Microorganism. *International Journal of ChemTech Research*. 2015, .7, 2, 769-779.
12. Oh, Y.; Lee, W.; Chung, H.; Yoon, J.; Cho, H. Syntheses of new pyridonecarboxylic acid derivatives containing 3-,5- or 6-quinolyl substituents at N-1 and their anti-HIV-RT activities. *J. Heterocyclic Chem* 1998, 35, 541-550.
13. Appelbaum, C.; Hunter, A. The fluoroquinolone antibacterials: past, present and future perspectives. *Int. J. Antimicrob. Agents* 2000, 16, 5-15.
14. Mizuki, Y.; Fujawara, I.; Yamaguchi, T. Pharmacokinetic interactions related to the chemical structures of fluoroquinolones. *J. Antimicrob. Chemother* 1996, 37 (Suppl.A), 41-55.
15. Ball, P. Quinolone generations: natural history or natural selection? *J. Antimicrob. Chemother* 2000, 46, 17-24.
16. Snaz-Nebot, V.; Valls, I.; Barbero, D.; Barbosa J. Acid-Base Behavior of Quinolones in Aqueous Acetonitrile Mixtures. *Acta Chem. Scand. A* 1997, 51, 896-903.
17. Pradeep, Y.; Joshi, Y.C.; Syntheses and spectral studies of novel ciprofloxacin derivatives. *Bull. Chem. Soc. Ethiop* 2008, 22(3), 459-464.
18. Dharmarajan, S.; Perumal, Y.; Jafar S-B.; Deshpande R.; Radha and Valakunja, N. Synthesis and antimycobacterial evaluation of various 7-substituted ciprofloxacin derivatives. *Bioorganic & Medicinal Chemistry* 2005, 13, 5774-5778.
19. Yadav, P.; Singhal, R.; Singh, S.; Joshi, Y. C. Synthesis and antimicrobial activity of thiazine derivatives. *Int J Pharm PharmSci*, 2013, 5, 171-174.
20. Bahram, L-E.; Saeed E-M.; Negar, O.; Mohammad, Ali, F-A.; Nasrin S-A.; Abbas S-H.; Alireza, F.; synthesis and Antibacterial Activity of New N-[2-(Thiophen-3 yl)ethyl] Piperazinyl Quinolones. *Chem. Pharm. Bull* 2007, 55(6) 894-898.
21. Fazel, S.; Alireza, F.; Hashim, S.; Nasrin, S.; Mohammad Ali, F.; Abbas, S. Synthesis and In-vitro Antibacterial Activities of Acetylanthracene and Acetylphenanthrene Derivatives of Some Fluoroquinolones. *Iranian Journal of Pharmaceutical Research* 2011, 10 (2), 225-231.
22. Igor, A.; Parshikov, D.; Moody, P.; Freeman, Jackson, L, Jr, A-J.; Williams, T-M.; Heinze, J-B. Formation of conjugates from ciprofloxacin and norfloxacin in cultures of *Trichoderma viride*. *Mycologia*, 2002, 94 (1), 1-5.
23. Aleksandra, B.; Radoslaw, S.; Urszula, K.; Komarnicka, Z-C.; Agnieszka, K.; Katarzyna, G.; Gabriela Bugla-Płoskon, 's.; Małgorzata J-B. Phosphine derivatives of ciprofloxacin and norfloxacin, a new class of potential therapeutic agents. *New J. Chem*, 2014, 38, 1062-1071.
24. Saurabh, D.; Krishna, C.; Roop, K.; Daman S.; Anil K.; Madhu, C. Synthesis and evaluation of Ciprofloxacin derivatives as diagnostic tools for bacterial infection by *Staphylococcus aureus*. *Metallomics*, 2009, 1, 409-417.
25. Eric, V.; Mark. B. Amide bond formation: beyond the myth of coupling reagents. *Chem. Soc. Rev* 2009, 38, 606-631.
26. Graul, A.; Castaner, J. "Atorvastatin calcium". *Drugs Future* 1997, 22, 956-968.
27. Patchett, A. Excursions in drug discovery. *J. Med. Chem* 1993, 36, 2051-2058.

28. Ananthanarayanan, S.; Tetreault, S.; Saint-Jean. A. Interaction of calcium channel antagonists with calcium: spectroscopic and modeling studies on diltiazem and its Ca²⁺ complex. *J. Med.Chem* 1993, 36, 1324-1332.
29. de Gasparo, M.; Whitebread, S. Binding of valsartan to mammalian angiotensin AT1 receptors *Regul. Pept* 1995, 59, 303-311.
30. Anjali T, Pusp R. S. G, Prateek P, Ankit K, Design, Synthesis, SAR, Docking and antibacterial evaluation: Aliphatic amide bridged 4-aminoquinoline clubbed 1,2,4- triazole derivatives. *International Journal of ChemTech Research*. 2016, 9, 3, 575-588.
31. Thathan J, Md.Afzal A, Design and Synthesis of Dual Inhibitors Targeting Gyrase B and Par E. *International Journal of ChemTech Research*. 2015,7, No.2, pp 711-715.
32. Hardik M, Ranjan , K, Synthesis and studies of some substituted pyrimidines. *International Journal of ChemTech Research*. 2015, 7, 01, 275-27.
33. Pechiamma M, Leena S, Ravichandran S, Synthesis, characterisation and screening of antimicrobial activity of metal complexes derived from the Mannich base, N-[1-morpholino (4-nitrobenzyl)] benzamide. *International Journal of ChemTech Research*. 2015, 7,01, 287-292.
34. Nadhir NA Jafar, Abbas, M.; Ammar, M. Synthesis of New Analogues of drug 'Monastrol' via Biginelli Reaction. *RJPBCS* 2015 6(5). 907-915.
35. Jursic, B-S.; Zdravkovdki, Z.A Simple Preparation of Amides (III) from Acids (I) and Amines (II) by Heating of Their Mixture. *Synth. Commun* 1993, 23, 19, 2761-2770.
36. Sultana, N.; Arayne, M-S.; Bushra, S.; Rizvi, S.; Haroon, U. Synthesis, Characterization and Biological Evaluations of Ciprofloxacin Carboxamide Analogues. *Bull. Korean Chem. Soc* 2011, 32, 2, 483-488.
37. Shafiee, A.; Haddad Zahmatkesh, M.; Mohammadhosseini, N.; Khalafy, J.; Emami, S.; Moshafi, MH.; Sorkhi, M.; Foroumadi, A. Synthesis and in-vitro antibacterial activity of N-piperazinyl quinolone derivatives with 5-chloro-2-thienyl group. *DARU. J. Pharm Sci.* 2008; 16(3) 189-195.
38. Amjad, M.; QandilLorca, Al-Zoubi.; Amal, G. Al-Bakri.; Haneen, A. Amawi.; Qosay, A. Al-Balas.; Abdulmalik, M. Alkatheri.; Abdulkareem, M. Albekairy. Synthesis, Antibacterial Evaluation and QSAR of α -Substituted-N4-Acetamides of Ciprofloxacin and Norfloxacin. *Antibiotics* 2014, 3, 244-269.
39. Dahiya, S.; Chuttani, Krishna.; Khar, K. R.; Saluja, D.; Mishra, K. A.; Chopra, M. *Metallomics*, 2009, 1, 409-417.
40. Castro, W.; Navarro, M.; Biot, C. Medicinal potential of ciprofloxacin and its derivatives. *Future Med. Chem* 2013, 5, 1, 81-96.
41. Pinte'r, G.; Horva'th, P.; Bujdoso', S.; Sztaricskai, F.; Ke'ki, S.; Zsuga, M.; Kardos, S.; Rozgonyi, F.; Herczegh, P. Synthesis and antimicrobial activity of ciprofloxacin and norfloxacin permanently bonded to polyethylene glycol by a thiourea linker. *The Journal of Antibiotics* 2009, 62, 113-116.
42. Sharma, P. C.; Jain, A.; Jain, S.; Pahwa, R.; Yar, M. S. Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects. *Journal of Enzyme Inhibition and Medicinal Chemistry* 2010, 25, 4, 577- 589.
43. EUCAST, Disk diffusion method for antimicrobial susceptibility testing. The European Committee on Antimicrobial Susceptibility Testing 2009, *Eucast version 1.0*, 1-10.
44. Youssef, M. M.; Amin, M. A. Microwave Assisted Synthesis of Some New Heterocyclic Spiro-Derivatives with Potential Antimicrobial and Antioxidant Activity. *Molecules* 2010, 15, 8827- 8840.
